<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03633227</url>
  </required_header>
  <id_info>
    <org_study_id>747-401</org_study_id>
    <nct_id>NCT03633227</nct_id>
  </id_info>
  <brief_title>Study of OCA Evaluating Pharmacokinetics and Safety in Patients With PBC and Hepatic Impairment</brief_title>
  <official_title>A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intercept Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intercept Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 4, randomized, double-blind, placebo-controlled study will evaluate the PK and&#xD;
      safety of OCA treatment in patients with primary biliary cholangitis (PBC) and moderate to&#xD;
      severe hepatic impairment over a 48 week treatment period. Patients who have completed their&#xD;
      48-week double blind treatment period will continue double-blind treatment until all&#xD;
      randomized patients have completed their 48-week treatment period and the database for that&#xD;
      period is locked. An open-label extension study in which all patients receive OCA will be&#xD;
      considered following review of blinded safety and PK data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to Ocaliva (obeticholic acid) US labeling update, the sponsor decided to terminate the&#xD;
    study.&#xD;
  </why_stopped>
  <start_date type="Actual">June 22, 2018</start_date>
  <completion_date type="Actual">July 9, 2021</completion_date>
  <primary_completion_date type="Actual">July 9, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate maximum concentration (Cmax) of OCA, its conjugates and total OCA (sum of OCA and its conjugates)</measure>
    <time_frame>Weeks 12, 18, 24, 30 and 48: 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, and 24 hours at</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate area under the concentration curve versus time curve from 0 to 24 hours (AUC 0-24) of OCA, its conjugates and total OCA</measure>
    <time_frame>24 hours at Day 1, and Weeks 12, 18, 24, 30, 36, and 48</time_frame>
    <description>Area under the concentration versus time curve from time 0 to 24 hours with measurable analyte concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate safety and tolerability as assessed by the incidence of treatment emergent adverse events and serious treatment emergent adverse events comparing OCA to placebo</measure>
    <time_frame>Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, 48, and every 3 months thereafter through approximately 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of OCA treatment compared to placebo on the model of end-stage liver disease (MELD) and its components</measure>
    <time_frame>Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, 48, and every 3 months thereafter through approximately 3 years</time_frame>
    <description>MELD Scores range from 6 [low risk] to 40 [high risk]. The three components of MELD (total bilirubin [mg/dL], serum creatinine[mg/dL], and INR) are input into the following equation to generate a MELD Score:&#xD;
MELD = 3.78×ln[total bilirubin (mg/dL)] + 11.2×ln[INR] + 9.57×ln[serum creatinine (mg/dL)] + 6.43</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of OCA treatment compared to placebo on Child-Pugh score and its components</measure>
    <time_frame>At Day 1, and Weeks 6, 12, 18, 24, 30, 36, and 48</time_frame>
    <description>The 5 components of the Child Pugh Score are scored on a scale of 1-3 by increasing severity and then summed together to calculate the total score (range: 5 [compensated cirrhosis] - 15 [decompensated cirrhosis]). The components of the Child Pugh Score are total bilirubin [mg/dL], serum albumin [g/dL], INR, Ascites [none-severe], hepatic encephalopathy [none-grade 4]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of OCA treatment compared to placebo on total bilirubin (mg/dL) and direct bilirubin (mg/dL)</measure>
    <time_frame>Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, 48, and every 3 months thereafter through approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of OCA treatment compared to placebo on alkaline phosphatase (U/L), alanine aminotransferase (U/L), aspartate transaminase (U/L), and gamma glutamyl transaminase (U/L)</measure>
    <time_frame>Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, 48, and every 3 months thereafter through approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of OCA treatment compared to placebo on platelets (109/L)</measure>
    <time_frame>Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, 48, and every 3 months thereafter through approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of OCA treatment compared to placebo on fibroblast growth factor-19 (pg/mL)</measure>
    <time_frame>Baseline, Screening, Day 1, Weeks 3, 6, 12, 18, 24, 30, 36, 42, 48, and every 3 months thereafter through approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>. Evaluate the effect of OCA treatment compared to placebo on 7α hydroxy-4-cholesten-3-one (ng/mL)</measure>
    <time_frame>Baseline, Weeks 3, 6, 12, 18, 24, 30, 36, 42, 48, and every 3 months thereafter through approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of OCA treatment compared to placebo on plasma bile acids (µmol/L)</measure>
    <time_frame>Weeks 3, 6, 12, 18, 24, 30, 36, 42, 48, and every 3 months thereafter through approximately 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Liver Cirrhosis, Biliary</condition>
  <arm_group>
    <arm_group_label>Obeticholic Acid (OCA) 5 mg to 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obeticholic Acid (OCA)</intervention_name>
    <description>Moderate and Severe hepatic impairment classified as Child-Pugh Class B and C: 5 mg tablet of OCA once weekly titrating up to 5 mg OCA twice weekly based on tolerability at 3 months and subsequently titrating up to a maximum dose of 10 mg OCA twice weekly based on safety and tolerability for the duration of the study.</description>
    <arm_group_label>Obeticholic Acid (OCA) 5 mg to 10 mg</arm_group_label>
    <other_name>6alpha-ethylchenodeoxycholic acid (6-ECDCA)</other_name>
    <other_name>INT-747</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One tablet twice weekly (or a lower frequency based on safety and tolerability) for the duration of the study</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A definite or probable diagnosis of PBC (consistent with American Association for the&#xD;
             Study of Liver Diseases [AASLD] and European Association for the Study of the Liver&#xD;
             [EASL] Practice Guidelines [Lindor 2009, EASL 2009]), defined as having ≥2 of the&#xD;
             following 3 diagnostic factors:&#xD;
&#xD;
               -  History of elevated ALP levels for at least 6 months&#xD;
&#xD;
               -  Positive antimitochondrial antibody (AMA) titer or if AMA negative or low titer&#xD;
                  (≤1:80), PBC specific antibodies (anti-GP210 and/or anti-SP100) and/or antibodies&#xD;
                  against the major M2 components (PDC-E2, 2-oxo-glutaric acid dehydrogenase&#xD;
                  complex)&#xD;
&#xD;
               -  Liver biopsy consistent with PBC (collected at any time prior to Screening)&#xD;
&#xD;
          2. Evidence of cirrhosis including at least one of the following:&#xD;
&#xD;
               -  Biopsy results consistent with PBC Stage 4&#xD;
&#xD;
               -  Liver stiffness as assessed by Transient Elastography (TE) Median Value ≥16.9kPa&#xD;
&#xD;
               -  Clinical evidence in the absence of acute liver failure consistent with cirrhosis&#xD;
                  including: gastroesophageal varices, ascites, radiological evidence of cirrhosis&#xD;
                  (nodular liver or enlargement of portal vein and splenomegaly)&#xD;
&#xD;
               -  Combined low platelet count (&lt;140 000/mm3) with&#xD;
&#xD;
                    -  persistent decrease in serum albumin, or&#xD;
&#xD;
                    -  elevation in prothrombin time /INR (not due to antithrombotic agent use), or&#xD;
&#xD;
                    -  elevated bilirubin (2× ULN)&#xD;
&#xD;
          3. Satisfy the criteria of the modified CP classification for hepatic impairment during&#xD;
             Screening:&#xD;
&#xD;
               -  Moderate: CP-B (Scores 7 to 9) or&#xD;
&#xD;
               -  Severe: CP-C (Scores 10 to 12)&#xD;
&#xD;
          4. MELD score of 6 to 24 at Screening&#xD;
&#xD;
          5. Taking UDCA for at least 12 months (stable dose for ≥3 months) prior to Day 1, or&#xD;
             unable to tolerate or unresponsive to UDCA (no UDCA for ≥3 months)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-cirrhotic or cirrhotic CP-A (Mild; Score 5 to 6)&#xD;
&#xD;
          2. History of liver transplant or organ transplant&#xD;
&#xD;
          3. History of alcohol or drug abuse within 12 months prior to Screening&#xD;
&#xD;
          4. Hepatic encephalopathy (as defined by a West Haven score of ≥2 [AASLD, EASL 2014])&#xD;
&#xD;
          5. History or presence of other concomitant liver diseases including:&#xD;
&#xD;
               -  Hepatitis C virus infection and RNA positive&#xD;
&#xD;
               -  Active hepatitis B infection; however, patients who have seroconverted (hepatitis&#xD;
                  B surface antigen and hepatitis B e antigen negative) may be included in this&#xD;
                  study after consultation with the medical monitor&#xD;
&#xD;
               -  Primary sclerosing cholangitis&#xD;
&#xD;
               -  Alcoholic liver disease&#xD;
&#xD;
               -  Definite autoimmune liver disease or overlap hepatitis&#xD;
&#xD;
               -  Gilbert's Syndrome&#xD;
&#xD;
          6. In the opinion of the Investigator, fluctuating or rapidly deteriorating hepatic&#xD;
             function prior to randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Harb, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Intercept Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Ddavis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schiff Center for Liver Diseases/ University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Center for Liver Diseases</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Liver Institute at Methodist Dallas Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine- Advanced Liver Therapies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Research Corporation at theTexas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Austral</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Aleman</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Britanico de Buenos Aires</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Gastroenterologia &quot;Dr Carlos Bonorino Udaondo&quot;</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aire</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Higea S.A.</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500DPS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Austral</name>
      <address>
        <city>Pilar</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial del Centenario</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Kingswood</city>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CUB Hospital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen UZA</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clínicas da Universidade Federal de Minas Gerais - UFMG</name>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Rio Grande</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>054003-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Leipzig AoR</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz, 4. Belgyogyaszat-Gasztroenterologia-Hepatologia</name>
      <address>
        <city>Bekescsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale (ASST) di Monza</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Ospedale Civile S. Agostino Estense - UO Medicina Metabolica</name>
      <address>
        <city>Modena</city>
        <zip>41126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kauno Klinikos</name>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klaipeda Seamen's Hospital</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santaros Klinikos</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paseo Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari I Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009 Jul;50(1):291-308. doi: 10.1002/hep.22906.</citation>
    <PMID>19554543</PMID>
  </reference>
  <reference>
    <citation>European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009 Aug;51(2):237-67. doi: 10.1016/j.jhep.2009.04.009. Epub 2009 Jun 6.</citation>
    <PMID>19501929</PMID>
  </reference>
  <reference>
    <citation>Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014 Aug;60(2):715-35. doi: 10.1002/hep.27210. Epub 2014 Jul 8.</citation>
    <PMID>25042402</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Biliary Cholangitis</keyword>
  <keyword>Primary Biliary Cirrhosis</keyword>
  <keyword>PBC</keyword>
  <keyword>Hepatic Impairment</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

